Valsartan Mitigates the Progression of Methotrexate-Induced Acute Kidney Injury in Rats via the Attenuation of Renal Inflammation and Oxidative Stress
Dina Kutbi,Riyadh S Almalki
DOI: https://doi.org/10.2147/jir.s456610
IF: 4.5
2024-04-11
Journal of Inflammation Research
Abstract:Dina Kutbi, 1, 2 Riyadh S Almalki 3 1 Department of Pharmacy, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia; 2 Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm AL-Qura University, Makkah, Saudi Arabia Correspondence: Dina Kutbi, Department of Pharmacy, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia, Email Background: Methotrexate (MTX) is a folic acid antagonist, commonly administered for the treatment of a variety of cancers. However, methotrexate toxicity including bone marrow suppression and hepatic and renal toxicity limits its use. Angiotensin AT 1 receptor blockers including Valsartan (Val) possess the ability to ameliorate MTX-induced toxicity through various mechanisms. In this study, we explored the potential reno-protective effects of Val against MTX-induced acute kidney injury in rats. Methods: Twenty-four Wistar rats were randomly segregated into 3 groups. Group 1 served as the control group and received an oral dose of 1mL/kg of normal saline. Group 2 received a single dose of 20 mg/kg of MTX intraperitoneally (IP) for 5 days. Group 3 received a single IP dose of 20 mg/kg of MTX followed by an oral dose of 10 mg/kg of Valsartan for 5 days. At the end of the experiment, the levels of serum kidney biomarkers, inflammatory and oxidative stress markers were accessed. Furthermore, the effect of MTX on kidney tissue histology was examined. Results and discussion: Our results showed that MTX treatment increased the level of serum kidney and inflammatory biomarkers and decreased the level of antioxidants SOD and GSH while increasing the lipid peroxidation contents. Furthermore, MTX treatment caused structural changes to kidney histology. However, the administration of Val significantly prevented these changes. Conclusion: Valsartan possesses nephroprotective potential and might serve as a potential therapeutic strategy against MTX-induced kidney injury. Keywords: acute kidney injury, inflammation, methotrexate, oxidative stress, renal toxicity, renoprotection The complex interactions between oxidants and antioxidant defense pathways lead to oxidative stress, which damages proteins, lipids, nucleic acids, and thiols. There is currently no agreement on a single optimal marker of oxidative stress, despite the fact that the existence of oxidative stress in individuals with chronic renal disease is widely established. Antihypertensive medication effects on oxidative stress have also not been prospectively investigated in patients with chronic renal failure. 1,2 Acute kidney injury (AKI) is a serious and potentially life-threatening condition resulting from a sudden decline in kidney function. This can happen for a variety of reasons, including dehydration, infection, and the use of certain medications such as over-the-counter medicines, and prescription drugs, renal/extra-renal surgeries. 3 AKI has continuously remained one of the causes of mortality in the world, especially among inpatients receiving treatments for chronic diseases, and this has become a growing concern in public health worldwide with an estimated incidence of 2–7% in hospitalized patients and a mortality rate of up to 50% in those with severe AKI. 4 Methotrexate (MTX) is a folate antagonist used to treat several malignant and autoimmune diseases. 5 High-dose methotrexate (HDMTX) 500–1000mg/m 2 is one of the major causes of kidney toxicity. Patients suffering from obesity, diabetes, heart failure, or older than 60 years are at high risk of AKI induced by MTX or HDMTX. 6 At high dosages in acidic conditions, MTX may produce crystals (7-hydroxy-MTX) which are insoluble in urine and precipitate within distal renal tubules. Additionally, substantial deposits of uric acid and calcium may cause acute renal failure caused by tumor rupture while taking chemotherapy. 7 The administration of MTX has also been shown to be linked to substantial side effects including depression, gastrointestinal symptoms such as nausea and vomiting, and cardiovascular problems like arrhythmia. MTX may also cause immunosuppression. 8 Currently, the available options for the treatment of HDMTX-induced toxicity include the use of glucarpidase and leucovorin. 9 Within 15 minutes of treatment, glucarpidase (carboxypeptidase G2) may hydrolyze circulating MTX into its inactive form, deoxyaminopteroic acid, and lower plasma MTX levels by >95%. 10 However, there are certain restrictions on the use of glucarpidase for HDMTX treatment. It has a relatively short half-life, limited availabil -Abstract Truncated-
immunology